On March 5, 2021 Australian TGA’s Access Consortium are considering changing the COVID-19 vaccine’s mRNA code during the pandemic, in a provisionally registered vaccine, and compare is to seasonal influenza vaccine changes, even though they are completely different technologies.
“On public health and scientific considerations, Regulatory Authorities do not consider an updated coronavirus vaccine to be an entirely novel product with the resulting requirement for lengthy full-blown clinical studies.”….”a regulatory approach like for seasonal updates for influenza vaccines can be taken”
“Since an updated vaccine variant will build on a previously authorised parent version with established quality, safety and efficacy; from a public health perspective, it may be justifiable to roll out the new vaccine candidate already in parallel with the previous version in absence of clinical immunogenicity and safety data while these studies are ongoing.”
It appears that since a “booster” has been granted TGA provisional approval, changing the mRNA code may not require much regulatory oversight!!! Yet a different protein could have profound cytotoxic implications.
It appears the regulatory agency is authorising the “vaccine platform” and not the “active ingredient” which mRNA code will force the body to manufacture. The body makes the “active ingredient”, that is unique for each vaccine, but apparently not according to the regulators.